光合生物醫學股份有限公司
Update：2026/11/12
Industries
Main Industry
Biotechnology
Main Product/Service
In addition to developing the Quad-functional Cancer Stem Cell Screening Platform (QCSP), 光合生物醫學股份有限公司 is also actively engaged in the research and development of targeted cancer therapies, introducing the preclinical PBX1 small molecule inhibitor B004. B004 targets PBX1 as its core target and aims to block the binding of PBX1 to DNA, thereby inhibiting transcription programs associated with cancer stem cells. By targeting the resistance, stemness, and metastatic mechanisms of cancer stem cells, it serves as a potential development solution for cancer therapeutics.
The content above was translated by Ai
Founded Year
2025
Unified Business No.
60492433
Status
Active
Number of Employees
2
Total Paid-in
Capital
36,550,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
光合生物醫學股份有限公司 is a novel biotech drug company focused on the development of targeted therapies for cancer stem cells (CSCs). The company's mission is to address the root causes of cancer recurrence, metastasis, and drug resistance. Through its proprietary cancer stem cell screening and expansion technology and high-throughput drug screening platform, it has successfully identified multiple first-in-class small molecule drug candidates, developing them to target cancer stem cell targets previously considered "undruggable."
The content above was translated by Ai
